ArticleEuropean heart journal. Cardiovascular Imaging2026
Associations and prognostic implications of myocardial tissue injury stages in ST-elevation myocardial infarction using the Canadian Cardiovascular Society classification.
Article in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
Abstract
aimsThe recently proposed Canadian Cardiovascular Society (CCS) classification categorizes post-infarction tissue injury into four stages, potentially improving risk stratification and guiding cardioprotective strategies. Its clinical and prognostic relevance in ST-elevation myocardial infarction (STEMI) remains unclear. We aimed to compare clinical characteristics across CCS stages and validate their prognostic implications in STEMI. METHODS AND
resultsWe analysed 1109 STEMI patients included in three prospective studies. Cardiac magnetic resonance (CMR) imaging was performed 3 (interquartile range 2-5) days after myocardial infarction (MI) and patients were classified as follows: Stage 1 (aborted MI), Stage 2 (MI with necrosis and absence of microvascular injury), Stage 3 (MI with necrosis and microvascular obstruction), and Stage 4 (MI with necrosis and intramyocardial haemorrhage). This analysis revealed distinct patterns of clinical presentation, biomarker profiles, and cardiac function across the different CCS stages. There were differences in adverse clinical event rates and mortality between CCS stages [major adverse cardiovascular event (MACE): 0.7%, 3.4%, 3.1%, and 15.7%, P < 0.001 and mortality: 0.7%, 1.7%, 0.9%, and 6.3%, P < 0.001]. The CCS stage had a moderate to good predictive value for MACE and mortality [area under the curve (AUC) 0.74 (95% CI: 0.68-0.80), P < 0.001 and AUC 0.71 (95% CI: 0.61-0.80), P < 0.001] at 12 months, respectively. CCS stages were independently associated with MACE in multivariable Cox regression [hazard ratio: 2.18 (95% CI: 1.70-2.78), P < 0.001].
conclusionThis study describes clinical characteristics across CCS stages and provides insights into their prognostic implications in a large cohort of STEMI patients reperfused by percutaneous coronary intervention. These data should inform the use of CCS stages in future trial designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.